Advanced Viral Research completes enrollment in diabetes study

By E. Janene Geiss

Philadelphia, May 12 - Advanced Viral Research Corp. said Friday that it completed enrollment of subjects in the first part of the phase 1 study in type 2 diabetic patients.

In this trial, 30 subjects with type 2 diabetes being treated with sulfonylureas and/or metformin have been enrolled. The primary objective is to explore the effect of daily doses 4.0 ml of AVR118 given subcutaneously on blood glucose compared to subjects not receiving AVR118, according to a company news release.

Earlier this year, the company said it amended the protocol for this study to include an additional 12 subjects at a dose of 1.0 ml of AVR118 given subcutaneously daily for 15 days, followed by one week of dosing every other day. Accrual of the additional 12 patients is currently ongoing, officials said.

Advanced Viral Research is a Yonkers, N.Y., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.